Sydney, Aug 25, 2017 AEST (ABN Newswire) - Regeneus Ltd (
ASX:RGS) CEO John Martin talks on the release of the financial results following the company's significant progress with Japanese partner Asahi Glass Ltd (AGC) (TYO:5201)
John Martin talks about the successful Progenza STEP trial and the granting of a Japanese patent for the company's platform technology.
Milestone payments made for the technology has moved the balance sheet into postitive revenue as the company prepares for licensing in Japan, with expectation of flow through licensing in other countries to follow.
Regeneus Ltd will be presenting to the BioJapan 2017 Conference in Yokohama from October 11 to October 13. To visit the conference website, please visit:
http://www.ics-expo.jp/biojapan/en/
To view the video interview, please visit:
http://www.abnnewswire.net/press/en/89647/rgs
About Regeneus Ltd
Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza(TM) and Sygenus. Visit www.regeneus.com.au for more information.
| ||
|
